HRMY Harmony Biosciences Holdings Forecast, Technical & Fundamental Analysis
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs... Show more
HRMY is expected to report earnings to fall 23.80% to 97 cents per share on November 03
Q3'26
Est.
$0.98
Q2'26
Beat
by $0.40
Q1'26
Missed
by $0.21
Q4'25
Missed
by $0.29
Q3'25
Beat
by $0.34
The last earnings report on August 04 showed earnings per share of $1.28, beating the estimate of 87 cents. With 94.29K shares outstanding, the current market capitalization sits at 2.23B.
A.I. Advisor
published General Information
General Information
a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders
A.I.dvisor indicates that over the last year, HRMY has been loosely correlated with ACAD. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if HRMY jumps, then ACAD could also see price increases.
HRMY in +10.04% Uptrend, rising for three consecutive days on August 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HRMY advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 27, 2026. You may want to consider a long position or call options on HRMY as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for HRMY just turned positive on August 04, 2026. Looking at past instances where HRMY's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
The 50-day moving average for HRMY moved above the 200-day moving average on July 01, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Aroon Indicator entered an Uptrend today. In of 215 cases where HRMY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for HRMY moved out of overbought territory on July 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRMY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
HRMY broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HRMY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.258) is normal, around the industry mean (20.024). P/E Ratio (12.537) is within average values for comparable stocks, (26.000). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.581). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (2.369) is also within normal values, averaging (449.295).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRMY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
